EBS

SEC source: 0001367644-25-000111 · wk-form4_1746232297.xml · nonDerivative · entry 1

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,517

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000107 · wk-form4_1746232253.xml · derivative · entry 2

Dayal Sujata Tyagi · CIK 0001536908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001367644-25-000107 · wk-form4_1746232253.xml · nonDerivative · entry 1

Dayal Sujata Tyagi · CIK 0001536908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,532

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000105 · wk-form4_1746232232.xml · derivative · entry 2

Harsanyi Zsolt · CIK 0001380184 · Director · Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001367644-25-000105 · wk-form4_1746232232.xml · nonDerivative · entry 1

Harsanyi Zsolt · CIK 0001380184 · Director · Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,732

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000104 · wk-form4_1746232222.xml · derivative · entry 2

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001367644-25-000104 · wk-form4_1746232222.xml · nonDerivative · entry 1

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,503

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000093 · wk-form4_1744238155.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,122

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000092 · wk-form4_1744238143.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,176

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000059 · wk-form4_1741817583.xml · nonDerivative · entry 1

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,482

SEC source: 0001367644-25-000060 · wk-form4_1741817592.xml · nonDerivative · entry 1

Fowler Neal Franklin · CIK 0001493692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,100

F1 · price: On March 12, 2025, Mr. Fowler sold an aggregate of 35,000 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $5.81 to $5.89. The Company maintains a record of the transactions and copies will be provided upon request.

SEC source: 0001367644-25-000058 · wk-form4_1741817572.xml · derivative · entry 2

PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,532,500

Underlying: Common Stock · 250,000 shares

Expires 2031-03-12

F1 · shares: Consists of an award of performance stock options granted under the company's Inducement Plan. These performance stock options vested in one annual installment on the day prior to the first anniversary of the date of grant based on the achievement of the $5 and $10 stock price performance hurdles as described in Mr. Papa's executive employment agreement dated February 19, 2024 (the "Papa Employment Agreement") and as certified by the company's Compensation Committee on February 12, 2025. Pursuant to the award, there remains 250,000 unvested performance stock options that are subject to a $15 stock price performance hurdle as described in the Papa Employment Agreement. Each performance stock option represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc. at the exercise price.

SEC source: 0001367644-25-000058 · wk-form4_1741817572.xml · derivative · entry 1

PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,282,500

Underlying: Common Stock · 250,000 shares

Expires 2031-03-12

F1 · shares: Consists of an award of performance stock options granted under the company's Inducement Plan. These performance stock options vested in one annual installment on the day prior to the first anniversary of the date of grant based on the achievement of the $5 and $10 stock price performance hurdles as described in Mr. Papa's executive employment agreement dated February 19, 2024 (the "Papa Employment Agreement") and as certified by the company's Compensation Committee on February 12, 2025. Pursuant to the award, there remains 250,000 unvested performance stock options that are subject to a $15 stock price performance hurdle as described in the Papa Employment Agreement. Each performance stock option represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc. at the exercise price.

SEC source: 0001367644-25-000050 · wk-form4_1741637867.xml · derivative · entry 2

Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,999

Underlying: Common Stock · 62,500 shares

Expires 2032-03-05

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-25-000050 · wk-form4_1741637867.xml · nonDerivative · entry 1

Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,982

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-25-000053 · wk-form4_1741637900.xml · derivative · entry 2

Perl Jessica · CIK 0002043716 · SVP, General Counsel, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,945

Underlying: Common Stock · 62,500 shares

Expires 2032-03-05

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-25-000053 · wk-form4_1741637900.xml · nonDerivative · entry 1

Perl Jessica · CIK 0002043716 · SVP, General Counsel, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,387

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-25-000048 · wk-form4_1741637843.xml · derivative · entry 2

PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,032,500

Underlying: Common Stock · 282,500 shares

Expires 2032-03-05

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-25-000048 · wk-form4_1741637843.xml · nonDerivative · entry 1

PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,500

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each performance stock unit represents a right to receive one share of common stock. The performance stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company and upon achievement with respect to Adjusted EBITDA for the 2025 fiscal year, as certified by the Compensation Committee following the performance period.

SEC source: 0001367644-25-000051 · wk-form4_1741637877.xml · derivative · entry 2

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 484,490

Underlying: Common Stock · 178,546 shares

Expires 2032-03-05

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-25-000051 · wk-form4_1741637877.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 299,225

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-25-000049 · wk-form4_1741637856.xml · derivative · entry 2

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,711

Underlying: Common Stock · 62,500 shares

Expires 2032-03-05

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-25-000049 · wk-form4_1741637856.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,975

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-25-000052 · wk-form4_1741637887.xml · derivative · entry 2

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,114

Underlying: Common Stock · 62,500 shares

Expires 2032-03-05

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-25-000052 · wk-form4_1741637887.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,335

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-25-000047 · wk-form4_1741637831.xml · derivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 249,613

Underlying: Common Stock · 62,500 shares

Expires 2032-03-05

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-25-000047 · wk-form4_1741637831.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,656

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-25-000089 · wk-form4a_1744237870.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,683

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F2 · balance_after: This Form 4/A is filed solely to correct the previously reported amount of securities beneficially owned following the reported transaction. The original Form 4 filing reported 109,975 due to a clerical error.

SEC source: 0001367644-25-000038 · wk-form4_1741383543.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,183

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000030 · wk-form4_1741122292.xml · nonDerivative · entry 3

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,337

F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000034 · wk-form4_1741122483.xml · nonDerivative · entry 3

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,156

F3 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000032 · wk-form4_1741122397.xml · nonDerivative · entry 2

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,835

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000030 · wk-form4_1741122292.xml · nonDerivative · entry 2

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,020

F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000032 · wk-form4_1741122397.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,951

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000030 · wk-form4_1741122292.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,093

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. On February 12, 2025, the final certification date, the Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 16,916 shares previously reported on March 1, 2022.

SEC source: 0001367644-25-000034 · wk-form4_1741122483.xml · nonDerivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,469

F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. On February 12, 2025, the final certification date, the Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 24,078 shares previously reported on December 9, 2022.

SEC source: 0001367644-25-000034 · wk-form4_1741122483.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,547

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. On February 12, 2025, the final certification date, the Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 5,913 shares previously reported on April 8, 2022.

SEC source: 0001367644-25-000012 · wk-form4_1739307685.xml · nonDerivative · entry 1

Perl Jessica · CIK 0002043716 · SVP, General Counsel, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,887

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-24-000193 · wk-form4_1734475436.xml · derivative · entry 2

Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,499

Underlying: Common Stock · 40,499 shares

Expires 2031-12-14

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-24-000193 · wk-form4_1734475436.xml · nonDerivative · entry 1

Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,482

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-24-000191 · wk-form4_1733864550.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,460

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-24-000186 · wk-form4_1731619131.xml · nonDerivative · entry 1

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,100

F1 · price: On November 12, 2024, Mr. DeGolyer sold an aggregate of 25,000 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $10.83 - $11.05. The Company maintains a record of the transactions and copies will be provided upon request.

SEC source: 0001367644-24-000184 · wk-form4_1731531882.xml · nonDerivative · entry 1

White Marvin L · CIK 0001493324 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,092

F1 · price: On November 11, 2024, Mr. White sold an aggregate of 14,287 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $11.84 - $12.11. The Company maintains a record of the transactions and copies will be provided upon request.

SEC source: 0001367644-24-000183 · wk-form4_1731531872.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,475

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-24-000164 · wk-form4_1729199070.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,009

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in one annual installment beginning on the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-24-000126 · wk-form4_1720816385.xml · nonDerivative · entry 1

Fox Jennifer Lynne · CIK 0001914879 · EVP, Ext Aff, GC, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,382

F1 · shares: Consists of restricted stock units granted under the company's Amended and Restated Stock Incentive Plan. These restricted stock units vest in one installment on the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-24-000127 · wk-form4_1720816397.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,107

F1 · shares: Consists of restricted stock units granted under the company's Amended and Restated Stock Incentive Plan. These restricted stock units vest in one installment on the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-24-000120 · wk-form4_1720641753.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,333

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-24-000108 · wk-form4_1718136649.xml · nonDerivative · entry 1

Fox Jennifer Lynne · CIK 0001914879 · EVP, Ext Aff, GC, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,382

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-24-000105 · wk-form4_1718136614.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,009

F1 · shares: Represents shares of common stock withheld to pay taxes.